Publications by authors named "Anne-Sophie Cabron"

Genetic variants in TMEM106B are a common risk factor for frontotemporal lobar degeneration and the most important modifier of disease risk in patients with progranulin (GRN) mutations (FTLD-GRN). TMEM106B is encoding a lysosomal transmembrane protein of unknown molecular function. How it mediates its disease-modifying function remains enigmatic.

View Article and Find Full Text PDF

Although extensively investigated, cancer is still one of the most devastating and lethal diseases in the modern world. Among different types, colorectal cancer (CRC) is most prevalent and mortal, making it an important subject of research. The metalloprotease ADAM17 has been implicated in the development of CRC due to its involvement in signaling pathways related to inflammation and cell proliferation.

View Article and Find Full Text PDF

Colorectal cancer is one of the most commonly diagnosed malignancies in the Western world and is associated with elevated expression and activity of epidermal growth factor receptors (EGF-R). The metalloproteinase ADAM17 is involved in EGF-R activation by processing EGF-R ligands from membrane-bound pro-ligands. Underlining the link between colon cancer and ADAM17, genetic intestinal cancer models in ADAM17-deficient mice show a reduced tumor burden.

View Article and Find Full Text PDF

A disintegrin and metalloproteinase (ADAM) 17 has been implicated in many shedding processes. Major substrates of ADAM17 are TNF-α, IL-6R, and ligands of the epidermal growth factor receptor. The essential role of the protease is emphasized by the fact that ADAM17 deficiency is lethal in mice.

View Article and Find Full Text PDF
Article Synopsis
  • - Colorectal cancer treatment using antibodies to block the epidermal growth factor receptor (EGF-R) has limited effectiveness due to compensatory mechanisms involving soluble ligands produced by ADAM17.
  • - In studies with mouse models lacking ADAM17, tumor development was significantly reduced, indicating that ADAM17 is crucial for EGF-R's role in cancer growth, particularly through the involvement of IL-6 signaling.
  • - This research suggests a potential new treatment approach for colorectal cancer that could overcome the challenges of resistance to current EGF-R-blocking therapies by targeting the underlying signaling pathways.
View Article and Find Full Text PDF